Conduit Pharmaceuticals (CDT) vs. Its Rivals Critical Survey

Conduit Pharmaceuticals (NASDAQ:CDT) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Conduit Pharmaceuticals to similar businesses based on the strength of its profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Volatility and Risk

Conduit Pharmaceuticals has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals’ rivals have a beta of 3.84, indicating that their average share price is 284% more volatile than the S&P 500.

Profitability

This table compares Conduit Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conduit Pharmaceuticals	N/A	N/A	-328.67%
Conduit Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Conduit Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conduit Pharmaceuticals	0	0	0	1	4.00
Conduit Pharmaceuticals Competitors	8426	22286	50481	1353	2.54

As a group, “Pharmaceutical preparations” companies have a potential upside of 243.77%. Given Conduit Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Conduit Pharmaceuticals has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Conduit Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Conduit Pharmaceuticals	N/A	-$540,000.00	-0.02
Conduit Pharmaceuticals Competitors	$9.89 billion	$136.37 million	-5.60

Conduit Pharmaceuticals’ rivals have higher revenue and earnings than Conduit Pharmaceuticals. Conduit Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 30.9% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Conduit Pharmaceuticals rivals beat Conduit Pharmaceuticals on 7 of the 13 factors compared.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.